Tenaya Therapeutics (TNYA) Cash & Equivalents (2020 - 2026)

Tenaya Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $80.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 50.43% year-over-year to $80.9 million; the TTM figure through Mar 2026 stood at $80.9 million (up 50.43% YoY), while the FY2025 annual figure was $100.5 million, up 2225.86% from the prior year.
• Cash & Equivalents was $80.9 million for Q1 2026 at Tenaya Therapeutics, down from $100.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $100.5 million in Q4 2025 to a low of $4.3 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $56.2 million across 5 years, with a median of $58.1 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 90.54% in 2024, then jumped 2225.86% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $95.3 million in 2022, then tumbled by 52.05% to $45.7 million in 2023, then plunged by 90.54% to $4.3 million in 2024, then surged by 2225.86% to $100.5 million in 2025, then declined by 19.55% to $80.9 million in 2026.
• The last three Cash & Equivalents figures came in at $80.9 million (Q1 2026), $100.5 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.